We performed Western blot analysis to confirm that treatment with paclitaxel as well as with doxorubicin, another chemotherapeutic agent that is commonly used to treat metastatic breast cancer, indeed robustly induced JNK signaling in breast cancer cells (Figs 5F and EV5C). The gene discussed is MAPK8; the disease is breast carcinoma.